Presenter's Information

Akiko Maehara, MD

Country USA
Specialty Interventional Cardiologist
  1. Prediction of Stent Expansion by IVUS and OCT
  2. Reclassification of Vulnerable Plaque Including Intraplaque Hemorrhage, Fissure, Healed Plaque and More
  3. Understanding MINOCA: Lessons and Case Examples from the HARP Registry
  4. Mechanical Issue of Left Main Stenting - Gap, Incomplete Crush, Deformation and More
  5. Year-In-Review: Intracoronary Imaging & Physiology
  6. Prepare & Predict: Role of Intracoronary Imaging for Calcified Lesion PCI
  7. Imaging Guidance for Calcified Lesion PCI
  8. Intravascular Imaging for Guidance of Plaque Modification Strategies in Calcified Coronary Artery
  9. The Role of Imaging in Calcified Lesions
  10. Coronary Imaging Perspective
  11. [Vulnerable Plaque Detection: What Is New in 2018?] NIRS
  12. Prognosis of "Yellow" Plaque In NIRS
  13. OCT-Guided PCI: OPINION, DOCTORS, ILUMIEN-III and ILUMIEN-IV
  14. How IVUS Improve LM and Bifurcation Outcomes?
  15. ILLUMEN-3 and Others: Imaging-Guided PCI Optimization
  16. How May Imaging Help in LM PCI?
  17. Differences in Plaque Morphology and Stability in STEMI, NSTE-ACS and Stable CAD
  18. Lessons from EXCEL IVUS Substudy
  19. Current and Future Imaging Diagnosis of Vulnerable Plaque
  20. New Findings from COLOR Registry
  21. Difference Between Coronary Artery Disease and Peripheral Artery Disease
  22. Clinical Utility of High-Resolution IVUS
  23. Do Malapposition, Stent Deformation and Fracture Link to Worse Clinical Outcome?
  24. Imaging Criteria of Vulnerable Plaques
  25. Vulnerable Plaque Detection by Grayscale IVUS and NIRS
  26. State-of-the-Art in High Resolution IVUS
  27. Clinical Trials by Using NIRS: Clinical Relevance and Prognostic Implication
  28. Beyond IVUS: OCT, NIRS, and Beyond
  29. NIR: PROSPECT II and PROSPECT ABSORB Trial
  30. NIRS-IVUS to Predict Long Term Outcome
  31. NIR
  32. It Is Time for Practical Use of High-resolution IVUS
  33. Role of IVUS and OCT in Left Main PCI
  34. IVUS-Guided PCI: ADAPT-DES and More...
  35. NIR Spectroscopy: Fundamentals and Diagnostic Applications
  36. Beyond IVUS: OCT, NIRS, and Beyond
  37. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - Yes, I Do. It Will Save Lives and Prevent ACS.
  38. Combined IVUS-NIR Spectroscopy: How to Predict Vulnerable Plaque and PCI Outcome
  39. High Resolution IVUS: See the Unseen!
  40. VH-IVUS: Native Vessel and Neointima
  41. IVUS: Pre-intervention and Post-intervention
  42. Various Types of Yellow Plaque Evaluated by NIRS/IVUS Catheter
  43. NIR
  44. IVUS: Postintervention
  45. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] Yes, I Like to Treat
  46. Near Infrared Spectroscopy
  47. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] Yes, I Do
  48. Neoatherosclerosis: Something New or Nothing New?
  49. [Does Morphology Predict Future Events?] Pro: Yes, Insights from PROSPECT
  50. IVUS Guided CTO Intervention
  51. Morphology and Distribution of Left Main and Non Left Main Bifurcation Atherosclerosis
  52. How Are Left Main and Non Left Main Bifurcations Unique: Insights from Imaging
  53. Temporal Stability of Focal Plaques: 2012 Imaging Insights
  54. Optical Coherence Tomography During PCI: A Research Tool or a Valued Clinical Asset?
  55. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] No, >0.80 Is Not Enough.
  56. Application of the 2nd Generation OCT in LM PCI
  57. Angioscopic and VH Characteristics of Culprits in ACS Patients
  58. What Would Be the Optimal IVUS Criteria to Predict Functional Significance?
  59. When and How To Assess Morphology and Function and Why?
  60. Tissue Characterization Using VH-IVUS; Pitfalls and Artifacts
  61. Expert Opinion for IVUS Use in Practice (Several IVUS Registry and PROSPECT Trial)
  62. Cardiovascular Imaging: “When/How/Which Imaging Modality Should We Choose?”
  63. IVUS Interpretation and Measurement: Focusing on What Important
  64. Assessment of Vulnerable Plaque by IVUS and VH-IVUS
  65. Role of MDCT in PCI Planning: Focus on CTO Treatment
  66. Limitations of IVUS: Why We Need Newer Imaging Techniques
Conference Slides
Category